In vitro induction of monoclonal antibody-defined T-cell markers in lymphocytes from immunodeficient children by synthetic serum thymic factor (FTS).

Bene MC, Faure G, Bordigoni P, Olive D, Duheille J

Clinical and experimental immunology1 May 1982Cited by 11 (Europe PMC)

PMID7049454PepBankPUB-07049454

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

4 results from studies that gave the peptide. No result from this study comes from people.

01LabEx vivo tissueActivity measurement
In lymphocytes from four responding immunodeficient children, FTS increased the percentage of cells bearing T-cell markers.
In plain wordsIn lab tests, FTS increased T-cell-marker-positive cells from four responding immunodeficient children.
Peptide
Thymulin (serum thymic factor)
Outcome
IncreaseCells bearing T-cell markers
Study
humann = 4
lymphocytes from children with ataxia telangectasia or unclassified immune deficiencies
Outcome group
Immune response · Immune and inflammation
Studied dose
0.25, 2.5 and 25 ng/mlAs given in this study (human).
Source sentences
Summary
The percentages of cells bearing T cell markers were elevated after incubation with FTS at graded concentrations (0.25, 2.5 and 25 ng/ml), by microlymphocytotoxicity or indirect immunofluorescence, using monoclonal anti-Lyt1 antibodies.
2 context sentences(design, population, supporting numbers)
Summary · context
In four cases, more than 30% of the non-T non-B cells acquired the Lyt1 T cell marker.
Summary · context
Lymphocytes from five children suffering from ataxia telangectasia or various unclassified immune deficiencies were tested in vitro for their sensitivity to synthetic serum thymic factor (FTS).
Report a problemFND-0704945401
02LabEx vivo tissueActivity measurement
In four immunodeficient children, more than 30% of non-T non-B cells acquired Lyt1 after FTS incubation.
In plain wordsIn lab tests, over 30% of non-T non-B cells from four immunodeficient donors acquired Lyt1 after FTS exposure.
Peptide
Thymulin (serum thymic factor)
Outcome
IncreaseLyt1 acquisition by non-T non-B cells
Study
humann = 4
lymphocytes from immunodeficient children
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Measurements
Cells acquiring Lyt1
> 30%
non-T non-B cells in four cases
Source sentences
Summary
In four cases, more than 30% of the non-T non-B cells acquired the Lyt1 T cell marker.
2 context sentences(design, population, supporting numbers)
Summary · context
The percentages of cells bearing T cell markers were elevated after incubation with FTS at graded concentrations (0.25, 2.5 and 25 ng/ml), by microlymphocytotoxicity or indirect immunofluorescence, using monoclonal anti-Lyt1 antibodies.
Summary · context
Lymphocytes from five children suffering from ataxia telangectasia or various unclassified immune deficiencies were tested in vitro for their sensitivity to synthetic serum thymic factor (FTS).
Report a problemFND-0704945402
03LabEx vivo tissueActivity measurement
FTS did not significantly increase T-marker-positive cells from two age-matched controls.
In plain wordsIn lab tests with cells from two age-matched controls, FTS did not significantly increase T-marker-positive cells.
Peptide
Thymulin (serum thymic factor)
Outcome
No significant changeT-marker-positive cells in controls
Study
humann = 2
lymphocytes from two age-matched controls
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
In the fifth child, who had a normal serum FTS level, and in two age-matched controls, there was no significant increase in the percentage of cells bearing the T marker.
1 context sentence(design, population, supporting numbers)
Summary · context
Lymphocytes from five children suffering from ataxia telangectasia or various unclassified immune deficiencies were tested in vitro for their sensitivity to synthetic serum thymic factor (FTS).
Report a problemFND-0704945406
04LabEx vivo tissueActivity measurement
FTS did not significantly increase T-marker-positive cells from the fifth child, who had normal serum FTS.
In plain wordsIn lab tests with cells from the fifth child, FTS did not significantly increase T-marker-positive cells.
Peptide
Thymulin (serum thymic factor)
Outcome
No significant changeT-marker-positive cells in fifth child
Study
humann = 1
lymphocytes from immunodeficient children
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
In the fifth child, who had a normal serum FTS level, and in two age-matched controls, there was no significant increase in the percentage of cells bearing the T marker.
1 context sentence(design, population, supporting numbers)
Summary · context
Lymphocytes from five children suffering from ataxia telangectasia or various unclassified immune deficiencies were tested in vitro for their sensitivity to synthetic serum thymic factor (FTS).
Report a problemFND-0704945405

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

05HumanEndogenous levelObservational studyOther
The four immunodeficient children whose cells acquired Lyt1 had low circulating FTS levels.
In plain wordsThe four responding children had low levels of the body's own FTS.
Peptide
Thymulin (serum thymic factor)
Outcome
DecreaseCirculating FTS levels in responding children
Study
n = 4
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
These four children had low levels of circulating FTS.
2 context sentences(design, population, supporting numbers)
Summary · context
In four cases, more than 30% of the non-T non-B cells acquired the Lyt1 T cell marker.
Summary · context
Lymphocytes from five children suffering from ataxia telangectasia or various unclassified immune deficiencies were tested in vitro for their sensitivity to synthetic serum thymic factor (FTS).
This result measures the body's own Thymulin (serum thymic factor). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0704945403
06HumanEndogenous levelObservational studyOther
The fifth immunodeficient child had a normal serum FTS level.
In plain wordsThe fifth child had a normal level of the body's own FTS.
Peptide
Thymulin (serum thymic factor)
Outcome
Not applicableSerum FTS level in fifth child
Study
n = 1
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
In the fifth child, who had a normal serum FTS level
1 context sentence(design, population, supporting numbers)
Summary · context
Lymphocytes from five children suffering from ataxia telangectasia or various unclassified immune deficiencies were tested in vitro for their sensitivity to synthetic serum thymic factor (FTS).
This result measures the body's own Thymulin (serum thymic factor). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0704945404

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.